SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

               Quarterly Report Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934
                For the Quarterly Period Ended September 30, 1996


                         Commission File Number 1-11831
                              SABRATEK CORPORATION
             (Exact name of registrant as specified in its charter)
                                   36-3700639

                                    DELAWARE
         (State or Other Jurisdiction of Incorporation or Organization)

                             5601 West Howard Street
                              Niles, Illinois 60714
          (Address of Principal Executive Offices, Including Zip Code)

                                 (847) 647-2760
              (Registrant's Telephone Number, Including Area Code)


Indicate  by check mark  whether  the  registrants  (1) have  filed all  reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934 (the  "Exchange  Act") during the  preceding 12 months (or for such shorter
period that the  registrants  were required to file such reports),  and (2) have
been subject to such filing requirements for the past 90 days.

                                       Yes      X           No


As of November 1, 1996, 8,089,924 shares of Sabratek  Corporation's Common Stock
were outstanding.


<PAGE>



                              SABRATEK CORPORATION

                                    FORM 10-Q
                For the Quarterly Period Ended September 30, 1996

                                TABLE OF CONTENTS


PART I            FINANCIAL INFORMATION
                                                                           Page
Item 1.           Financial Statements

                  Balance Sheet
                  September 30, 1996 (Unaudited) and December 31, 1995....   3

                  Statements of Operations
                  Three and Nine Months Ended September 30, 1996 and
                  September 30, 1995 (Unaudited)..........................   4

                  Statements of Cash Flows
                  Nine Months Ended September 30, 1996 and
                  September 30, 1995 (Unaudited)..........................   5

                  Notes to Financial Statements (Unaudited)...............   6

Item 2.           Management's Discussion and Analysis of Financial
                  Condition and Results of Operations.....................   9


PART II           OTHER INFORMATION.......................................  13


                                      - 2 -

<PAGE>



                              SABRATEK CORPORATION
                                 BALANCE SHEETS
                        (In thousands, except share data)

<TABLE>
<CAPTION>
                                                                            September 30,             
                                                                                 1996                December 31,
                                                                              (Unaudited)                1995
                                                                              -----------                ----
                                                                           
                  ASSETS
<S>                                                                                  <C>                            <C>
Cash and cash equivalents                                                            $ 9,504                        $8
Short-term investment in marketable securities                                         6,981                         -
Receivables:
   Trade, net of allowance for doubtful accounts of
   $110,412 and $187,969 at September 30, 1996 and
   December 31, 1995, respectively                                                     4,911                       766
   Due from related party                                                                865                       576
   Other                                                                                 121                         -
                                                                                    --------                  --------
Total receivables                                                                      5,897                     1,342
                                                                                     -------                    ------
Inventories                                                                            3,991                     1,825
Other current assets                                                                     483                        51
                                                                                    --------                   -------
Total current assets                                                                  26,856                     3,226
                                                                                     -------                    ------
Property, plant and equipment, net                                                       821                       902
Long-term investment in marketable securities                                          3,006                         -
Other                                                                                     96                        51
                                                                                   ---------                   -------
Total assets                                                                         $30,779                    $4,179
                                                                                     =======                    ======

                  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Short term debt                                                                     $    168                      $621
Current portion of capital lease obligation                                              151                       151
Current portion of long-term debt                                                          2                         3
Accounts payable                                                                       1,500                     2,377
Accrued expenses:
    Payroll & commissions                                                                700                       191
    Warranty                                                                             206                       229
    Other                                                                                 64                       287
Deferred rent                                                                             32                        32
Deferred revenue                                                                          81                       125
Due to affiliated company                                                                229                       312
                                                                                   ---------                   -------
Total current liabilities                                                              3,133                     4,328
                                                                                    --------                    ------
Long-term capital lease obligation                                                        11                       149
Long-term debt                                                                             3                     2,362
Accrued interest                                                                           -                       161
                                                                                   ---------                   -------
Total liabilities                                                                      3,147                     7,000
                                                                                     -------                    ------
Stockholders' equity (deficit)
   Convertible preferred stock, issued and outstanding;
    1,768,129 at December 31, 1995                                                         -                        18
   Common stock, issued and outstanding; 8,064,209 at
    September 30, 1996, 1,718,458 at December 31, 1995                                    81                        17
   Deferred compensation grant options                                                     -                         -
   Additional paid-in capital                                                         42,357                    10,709
   Note receivable from stockholder                                                        -                     (113)
   Deferred compensation                                                                (18)                         -
   Accumulated deficit                                                              (14,788)                  (13,452)
                                                                                   ---------                  --------
   Total stockholders' equity (deficit)                                               27,632                   (2,821)
                                                                                    --------                 ---------

                                                                                     $30,779                    $4,179
                                                                                     =======                   =======

</TABLE>
                       See accompanying notes to financial statements.

                                      - 3 -
<PAGE>



                              SABRATEK CORPORATION
                            STATEMENTS OF OPERATIONS
                      (In thousands, except per share data)
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                  Three Months Ended                           Nine Months Ended
                                                    September 30,                                September 30,
                                    -------------------------------------------------------------------------------------------
                                              1996                  1995                  1996                   1995
                                    -------------------------------------------------------------------------------------------
<S>                                              <C>                   <C>                   <C>                   <C>    
Net sales                                        $4,874                $  640                $11,589               $ 2,633

Cost of sales                                     2,487                   552                  5,832                 2,008
                                    -------------------------------------------------------------------------------------------
Gross margin                                      2,387                    88                  5,757                   625

Selling, general and
administrative expenses                           2,275                 1,497                  5,528                 4,924
                                    -------------------------------------------------------------------------------------------
Operating income (loss)                             112               (1,409)                    229               (4,299)
                                    -------------------------------------------------------------------------------------------
Other income (expense):
 Interest income                                    330                    4                    345                    10
 Interest expense                                  (48)                  (60)                  (285)                  (93)
 Stock appreciation rights                            -                    -                 (1,628)                    -
 Other                                                -                  (21)                     3                   (64)
                                    -------------------------------------------------------------------------------------------
Net income (loss)                                $  394              $(1,486)               $(1,336)              $(4,446)
                                    ===========================================================================================

Weighted average shares
outstanding                                       9,072                 4,130                  7,163                 3,993
                                    ===========================================================================================

Net income (loss) per share                      $ 0.04               $ (0.36)               $ (0.19)              $ (1.11)
                                    ===========================================================================================

</TABLE>

                       See accompanying notes to financial statements.

                                      - 4 -

<PAGE>



                              SABRATEK CORPORATION
                            STATEMENTS OF CASH FLOWS
                                 (In thousands)
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                                                                                    Nine Months Ended
                                                                 --------------------------------------------------------
                                                                        September 30,               September 30,
                                                                             1996                       1995
                                                                 --------------------------------------------------------
<S>                                                                             <C>                           <C>      
Cash flows from operating activities
      Net loss                                                                   $(1,336)                     ($4,446)
      Adjustments to reconcile net loss to net cash used
      in operating activities:
           Depreciation and amortization                                             231                          127
           Deferred compensation                                                       2                            -
           Stock appreciation rights expense                                       1,628                            -
           Provision for bad debts                                                    46                          114
           Changes in assets and liabilities
                Receivables                                                       (4,477)                        (134)
                Deferred revenue                                                     (75)                         125
                Inventories                                                       (2,166)                        (684)
                Advances to stockholders                                               -                          125
                Accounts payable                                                    (877)                         814
                Accrued expenses                                                      263                         158
                Due to affiliated company                                            (83)                         (92)
                Other                                                               (431)                          30
                                                                 --------------------------------------------------------
Net cash used in operating activities                                             (7,275)                      (3,863)
                                                                 --------------------------------------------------------
Cash flows from investing activities:
      Purchases of property, plant and equipment                                    (196)                        (505)
      Purchase of marketable securities                                           (9,987)                           -
                                                                 --------------------------------------------------------
Net cash used in investing activities                                            (10,183)                        (505)
                                                                 --------------------------------------------------------
Cash flows from financing activities:
      Proceeds from issuance of short-term debt                                      168                          218
      Repayment of short-term debt                                                  (621)                           -
      Repayment of long-term debt                                                   (351)                          (2)
      Proceeds from issuance of long-term debt                                     1,570                        1,775
      Payment of stock appreciation rights                                        (1,628)                           -
      Payments of capital lease obligations, net                                    (138)                        (107)
      Proceeds of capital lease, net                                                    -                         185
      Proceeds from issuance of stock, net                                         27,954                       1,999
                                                                 --------------------------------------------------------
Net cash provided by financing activities                                          26,954                       4,068
                                                                 --------------------------------------------------------
Increase (decrease) in cash                                                         9,496                       (300)
Cash and cash equivalents at beginning of year                                          8                         765
                                                                 --------------------------------------------------------
Cash and cash equivalents at end of year                                           $9,504                       $ 465
                                                                 ========================================================
</TABLE>

                       See accompanying notes to financial statements.

                                      - 5 -

<PAGE>



                              SABRATEK CORPORATION


                          NOTES TO FINANCIAL STATEMENTS

                               September 30, 1996
                                   (UNAUDITED)

(1)      Financial Statements

The  financial  statements  included  herein have been  prepared by the Company,
without audit,  and include all adjustments of a normal  recurring  nature which
are,  in the  opinion of  management,  necessary  for fair  presentation  of the
results of operations for the three month and nine month periods ended September
30, 1996 and 1995 pursuant to the rules and  regulations  of the  Securities and
Exchange  Commission.  Certain  information  and footnote  disclosures  normally
included in financial  statements prepared in accordance with generally accepted
accounting  principles have been condensed or omitted pursuant to such rules and
regulations,  although  the  Company  believes  that  the  disclosures  in these
financial  statements  are  adequate  to  make  the  information  presented  not
misleading.  These financial  statements  should be read in conjunction with the
Company's  financial  statements and the notes thereto included in the Company's
Form S-1  Registration  Statement (No.  333-3866)  filed by the Company with the
Securities  and  Exchange  Commission.  The results of  operations  for the nine
months ended  September 30, 1996 are not  necessarily  indicative of the results
that may be expected for the year ending December 31, 1996.

(2)      Initial Public Offering

In June,  1996, the Company  completed an initial  public  offering of 2,875,000
shares of Common Stock, par value $0.01, at a price of $10.00,  with proceeds to
the Company of $26,737,500 after  underwriters'  discounts and commissions.  The
Company's  shares  are  traded on the Nasdaq  National  Market  under the symbol
"SBTK."

(3)      Cash and Cash Equivalents

Cash and cash  equivalents  represent  funds in demand  deposits,  money  market
accounts and short-term bond mutual funds. Also included are U.S. Treasury Bills
and U.S. Treasury Notes to the extent they mature within ninety days.

(4)      Short-term and Long-term Investment in Marketable Securities

The  following  table  summarizes   short-term  and  long-term   investments  in
marketable securities as of September 30, 1996:


                                      - 6 -

<PAGE>



                                  Less than         1-2
         (in thousands)            1 Year          Years           Total
                                  ---------        -----           -----

         U.S. Treasury Bills      $4,981          $  -             $4,981

         U.S. Treasury Notes       2,000           3,006            5,006
                                  ---------------------------------------

                                  $6,981          $3,006           $9,987
                                  =======================================



The above  securities are classified as  available-for-sale  and are reported at
fair value. As of the balance sheet date, fair value  approximated cost, whereby
no unrealized gain or loss has been recorded.

(5)      Long-term Debt

Immediately  following the initial public offering,  subordinated  debentures in
the  principal  amount  of  $350,000,  plus  remaining  interest,  were  repaid.
Approximately $26,530 of interest was paid in the form of 5,574 shares of Common
Stock, as originally provided for in certain debentures.

Upon the  closing  of the  initial  public  offering,  convertible  subordinated
debentures in the principal  amount of $3,012,793,  along with accrued  interest
thereon of $337,680,  were  converted  into  1,202,965  shares of Common  Stock.
Certain debentures provided for a conversion premium that substantially  reduced
the stated conversion price.

(6)      Series A Preferred Stock

Upon the  closing  of the  initial  public  offering,  all  1,768,129  shares of
outstanding Series A Preferred Stock were converted into 1,838,113 shares of the
Company's Common Stock, including anti-dilutive adjustments.

(7)      Warrants

On June 27,  1996 a  warrant  was  exercised  for 9,454  shares of Common  Stock
providing proceeds to the Company of $45,000.

(8)      Supplemental Disclosures of Cash Flow Information

Cash paid for interest during the nine month period ended September 30, 1996 was
$81,704.

In  February,  1996,  the  Company  issued  124,488  shares of  Common  Stock in
satisfaction  of accrued  liabilities  in the amount of  $592,500  for  services
rendered in 1995.

During the nine months ended September 30, 1996, the Company  retired  aggregate
long-term  debt  principal  of  $3,597,793   and  satisfied   accrued   interest
obligations on long-term debt of $364,210,  in exchange for 1,331,451  shares of
Common Stock, in aggregate.

                                      - 7 -

<PAGE>




(9)      Stock Options

During the three month  period ended  September  30,  1996,  stock  options were
granted for 55,000 shares of Common Stock under the Sabratek Corporation Amended
and  Restated  1993 Stock Option  Plan,  at an exercise  price equal to the fair
market  value on the date of grant.  The stock  options  vest over a  multi-year
period.

(10)     Weighted Average Shares

Weighted  average shares  outstanding for the three month period ended September
30, 1996 are  calculated on a fully diluted  basis  applying the  treasury-stock
method for options and warrants outstanding.

Weighted  average shares  outstanding  for the nine month period ended September
30, 1996 are  calculated  pursuant to Securities and Exchange  Commission  Staff
Accounting  Bulletin  No. 83 for stock  options  and  warrants  outstanding  and
pro-rated based on the date of the initial public  offering.  Other Common Stock
equivalent  shares  from  stock  options  and  warrants  are  excluded  from the
computation because their effect is anti-dilutive.

                                      - 8 -

<PAGE>



Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations

                                   The Company

         Sabratek Corporation (the "Company" or "Sabratek")  develops,  produces
and markets technologically advanced, user friendly, interactive therapeutic and
diagnostic  medical  systems  designed  specifically  to meet  the  needs of the
alternate-site health care market. The Company's multitherapy infusion and other
systems reduce operating costs while improving the delivery and quality of care,
allowing  high-acuity  patients  to  be  treated  in  alternate-site   settings.
Sabratek's  proprietary  MediVIEW (TM) health care  information  system provides
remote programming as well as real-time  diagnostic and therapeutic data capture
capabilities, allowing caregivers to monitor patient compliance more effectively
and  allowing  providers  to  develop  outcome  analyses  and  optimal  clinical
protocols.  The Company has designed its integrated hardware and software system
to permit  providers to achieve  cost-effective  movement of patients  along the
continuum of alternate-site health care settings.

         Sabratek's   revenues   are   currently   derived  from  sales  of  its
multi-therapy infusion pumps, related disposables and accessories, Pumpmaster IV
pump diagnostic device and MediVIEW software and peripherals,  all of which make
up the  Sabratek  Seamless  Delivery  System.  The  Company is in the process of
expanding  the products that are offered  under the MediVIEW  software  platform
with the  strategy of  creating a "virtual"  hospital  room,  where  high-acuity
patients  can  receive   high-quality,   cost  effective  care  outside  of  the
traditional hospital setting.

         Sabratek's strategy focuses  specifically on the alternate-site  health
care market, which it believes will continue to experience significant growth as
managed care payors continue to move patients to the  lowest-cost  care setting.
Such growth may be attributed to increasing  cost-containment  pressures,  along
with  advances in medical  technology,  that have  transitioned  the delivery of
health care away from the traditional  acute-care setting to more cost-effective
sites. The alternate-site market includes,  among other things, the provision of
services  rendered  in various  settings,  including  the  patient's  residence,
sub-acute care facilities,  nursing homes, outpatient clinics,  dialysis centers
and hospice facilities.  The Company currently markets its products domestically
to national,  regional and local alternate-site  health care providers through a
direct sales force and a network of specialized  alternate-site medical products
distributors.  The Company  also markets its  products  internationally  through
distributors in Europe, Asia, South America and the Middle East.

         The following narrative discusses the results of operations,  liquidity
and capital resources for Sabratek Corporation.


                              Results of Operations

Three Months Ended September 30, 1996 vs. Three Months Ended September 30,1995
and Nine Months Ended September 30,1996 vs. Nine Months Ended September 30,1995
-------------------------------------------------------------------------------

         Net Sales.  Net sales  increased  to $4.9  million  for the three month
period  ended  September  30, 1996 as  compared to $640,000  for the three month
period ended  September  30, 1995,  an increase of 661%.  Net sales for the nine
month period ended September 30, 1996 were $11.6 million as

                                      - 9 -

<PAGE>



compared to $2.6 million for the nine month period ended  September 30, 1995, an
increase of $9.0 million,  or 346%.  Approximately  $5.7 million of the increase
during the nine  month  period  ended  September  30,  1996 is  attributable  to
incremental sales volume of the 3030 Stationary Pump and related  disposables to
regional and national  accounts in the  alternate-site  health care market.  The
balance of the  increase  for the nine month  period  ended  September  30, 1996
resulted from the addition of the 6060 Ambulatory Pump,  disposables and related
products first introduced in the fourth quarter of 1995.

         Cost of Sales. Cost of sales increased $1.9 million to $2.5 million for
the three months ended  September 30, 1996 as compared to $552,000 for the three
months ended September 30, 1995, an increase of 350%. Cost of sales for the nine
month  period  ended  September  30,  1996 was $5.8  million as compared to $2.0
million  for the nine  months  ended  September  30,  1995,  an increase of $3.8
million,  or 190%.  The  increase  for both  comparative  periods was  primarily
attributable to incremental sales volume.

         Gross Margin.  Gross margin for the three month period ended  September
30, 1996 was $2.4  million as  compared  to $88,000  for the three month  period
ended  September  30,  1995,  an  increase of $2.3  million.  For the nine month
periods ended  September 30, 1996 and 1995,  gross margins were $5.8 million and
$625,000, respectively. Gross margin as a percent of sales was 49% for the three
months  ended  September  30, 1996 as compared to 14% for the three months ended
September 30, 1995. For the nine months ended September 30, 1996 and 1995, gross
margins as a percent of sales were 50% and 24%,  respectively.  The  increase in
gross  margin,  both  absolute and as a percent of sales,  was due  primarily to
increased  sales  volume  and the  variable  contribution  margin  thereon  and,
secondarily, to higher average pricing levels.

         Selling,  General and  Administrative  Expenses.  Selling,  general and
administrative  expenses increased $778,000 to $2.3 million for the three months
ended  September 30, 1996 as compared to $1.5 million for the three months ended
September  30, 1995,  an increase of 52%.  Selling,  general and  administrative
expenses for the nine month period ended September 30, 1996 were $5.5 million as
compared to $4.9 million for the nine month period ended  September 30, 1995. As
a percent of sales for the three  month  periods  ended  September  30, 1996 and
1995,  selling,   general  and  administrative   expenses  were  47%  and  234%,
respectively.  Expansion  of the  Company's  sales and  clinical  support  staff
represented  incremental  expenses of approximately $1.1 million during the nine
month period ended September 30, 1996 as compared to the nine month period ended
September  30,  1995,  which was  partly  offset by the  absence  of  financing,
marketing,  and  development  consulting  fees incurred  during the  comparative
period of 1995.

         Operating  Income  (Loss).  The Company  reported  operating  income of
$112,000  for the three  months  ended  September  30,  1996 as  compared  to an
operating  loss of $1.4 million for the three months ended  September  30, 1995.
For the nine month  period  ended  September  30,  1996,  the  Company  reported
operating  income of $229,000  versus an operating  loss of $4.3 million for the
nine month period ended  September  30, 1995.  The primary  factors in achieving
operating  profitability,  as  discussed  above,  are the  addition  of the 6060
Ambulatory Pump product line in the fourth quarter of 1995 and increased  volume
of existing products in the comparative periods.


                                     - 10 -

<PAGE>



         Interest  Income.  Interest income  increased to $330,000 for the three
month  period  ended  September  30, 1996 from $4,000 for the three month period
ended  September 30, 1995.  For the nine month period ended  September 30, 1996,
interest  income  increased  to $345,000  from $10,000 for the nine month period
ended September 30, 1995. The substantial  increase for both comparative periods
is due to the investment  interest on unused proceeds from the Company's initial
public offering in June, 1996.

         Interest Expense. Interest expense decreased $12,000 to $48,000 for the
three  months  ended  September  30,  1996 as  compared to $60,000 for the three
months ended  September 30, 1995. For the nine month periods ended September 30,
1996 and 1995,  interest  expense was $285,000 and  $93,000,  respectively.  The
decrease  during the three month period ended September 30, 1996 is attributable
to the  repayment  and  conversion of  substantially  all long-term  debt of the
Company subsequent to the Company's initial public offering in June, 1996.

         Income Tax  Provision.  Due to net  losses  for the nine month  periods
ended  September  30,  1996 and 1995,  the  Company did not incur any federal or
state income tax  liability for such  periods.  The Company  currently has a net
operating loss  carryforward in excess of $13 million;  however,  utilization of
such depends on future  earnings and will be subject to annual  limitations as a
result of changes that have occurred in the Company's ownership.

         Net Income (Loss).  Net income for the three months ended September 30,
1996 was $394,000 as compared to a net loss of $1.5 million for the three months
ended  September 30, 1995.  Net income for the three months ended  September 30,
1996 was achieved  primarily  as a result of increased  unit sales volume of new
and existing products and the corresponding contribution margin thereon. The net
loss for the nine months ended  September 30, 1996 was $1.3 million versus a net
loss of $4.4  million for the nine month period ended  September  30, 1995.  The
nine month period ended September 30, 1996 includes a  non-recurring  charge for
stock appreciation rights of $1.6 million.

                         Liquidity and Capital Resources

         In June,  1996, the Company  completed an initial public  offering with
proceeds of $26,737,500,  after underwriters'  discounts and commissions.  As of
September 30, 1996,  unused proceeds were invested in U.S.  Treasury Bills, U.S.
Treasury Notes, a short-term bond mutual fund as well as a money market account.

         As of September 30, 1996, the Company had approximately  $19,491,000 in
cash, cash equivalents,  short-term and long-term marketable  securities and had
net working capital of  approximately  $23,723,000.  The Company  terminated its
credit  facility  with  Sterling  Business  Credit during the three month period
ended  September  30,  1996.  It is the  Company's  intention  to  secure a more
favorable credit facility in the near future; however, due to the dynamic nature
and  inherent  uncertainties  of economic  and credit  markets,  there can be no
assurance that such intentions will be realized.

         The Company used cash in its operations of  approximately  $7.3 million
for the nine month period ended  September 30, 1996. Cash used in operations for
the period exceeds the Company's

                                     - 11 -

<PAGE>



operating  results for the same period  due,  primarily,  to the growth in trade
accounts  receivable and  inventories as a result,  respectively,  of actual and
anticipated growth in sales volume.

         The Company  believes that its  financial  assets will be sufficient to
fund its operations for the foreseeable  future.  Further  liquidity and capital
resources  could be  adversely  influenced  by  certain  factors  including  the
Company's   dependence  on  a  relatively  new  customer  base,   regulatory  or
legislative  changes  pertaining  to health  care,  product  liability  exposure
regarding the delivery of medication,  dependence on future product development,
and  others.  There  can be no  assurance  that the  Company  will  not  require
additional  financing and may, in the future, seek additional funds through bank
facilities, debt or equity offerings and to the extent such additional financing
is not  available,  the Company  could suffer  material  adverse  effects to its
financial condition and the results of its operations.

                                     - 12 -

<PAGE>



                                     PART II
                                OTHER INFORMATION

              All of the  information  which  would be  required  in response to
Items 1, 2, 4 and 5 is incorporated  by reference to the Company's  Registration
Statement on Form S-1,  declared  effective by the United States  Securities and
Exchange Commission on June 21, 1996 (File No. 333-3866).

Item 6. Exhibits and Reports on Form 8-K

(a)           Exhibits

<TABLE>
<CAPTION>
 Exhibit                                                       Page Number          Incorporation
 Number                     Description of Documents         (if applicable)         by Reference
                                                                                   (if applicable)
<S>                                                               <C>                    <C>
  3(i)    Articles of Incorporation                                                       +
  3(ii)   ByLaws                                                                          +
   10     Material contracts                                                              +
  11.1    Statement re: computation of per share earnings          15
   27     Financial Data Schedule                                  16
</TABLE>


+    Incorporated by reference to the Company's  Registration  Statement on Form
     S-1,  declared  effective  by the  Commission  on June 21,  1996  (File No.
     333-3866).


(b)  Sabratek  Corporation  has not filed any  reports  on Form 8-K  during  the
     quarterly period ended September 30, 1996.


                                     - 13 -

<PAGE>



                                   SIGNATURES



         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                      SABRATEK CORPORATION



Date:  November 13, 1996             By:/s/ K. Shan Padda
                                         K. Shan Padda
                                         Chairman and Chief Executive Officer



         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
this report has been signed by the undersigned, in his capacity as the principal
financial officer of the registrant.



Date:  November 13, 1996             By:/s/ Stephen L. Holden
                                        Stephen L. Holden
                                        Principal Financial Officer



         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
this report has been  signed by the  undersigned,  in his  capacity as the chief
accounting officer of the registrant.



Date:  November 13, 1996             By:/s/ Scott Skooglund
                                        Scott Skooglund
                                        Chief Accounting Officer

                                     - 14 -